Specialized Combination Therapies for BPH/LUTS in Niche Environments
Legal Citation
Summary of the Inventive Concept
Adaptation of combination mast cell inhibition for treatment of BPH/LUTS in unique operational environments, including remote areas, high-security facilities, extreme weather conditions, high-altitude environments, and areas with limited access to medical care.
Background and Problem Solved
The original patent addresses the treatment of BPH/LUTS using combination therapies, but it lacks consideration for specific, narrow markets or unique operational environments. The new inventive concept addresses this limitation by providing specialized combination therapies tailored to these niche environments.
Detailed Description of the Inventive Concept
The inventive concept comprises portable combination therapy devices, kits, and systems designed for use in areas with limited medical infrastructure, high-security facilities, extreme weather conditions, high-altitude environments, and areas with limited access to medical care. These specialized solutions incorporate mast cell inhibitors and histamine receptor antagonists, ensuring effective treatment of BPH/LUTS in these unique environments.
Novelty and Inventive Step
The new claims introduce novel adaptations of the original combination therapies, providing non-obvious solutions for treating BPH/LUTS in niche environments. The inventive concept's value lies in its ability to address the specific challenges and limitations of these environments, thereby expanding the reach and accessibility of combination therapies.
Alternative Embodiments and Variations
Alternative embodiments may include wearable devices, injectable formulations, or oral medications tailored to specific environments. Variations could include the use of different mast cell inhibitors or histamine receptor antagonists, or the incorporation of additional therapeutic agents to enhance treatment outcomes.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and medical device industries, particularly in markets focused on remote healthcare, disaster relief, and specialized medical services. The target industries include healthcare providers, medical device manufacturers, and pharmaceutical companies operating in these niche environments.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical therapeutics, specifically urology and pharmacological treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), involving pharmaceutical formulation, drug delivery systems, and medical device design
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or clinical pharmacologist with expertise in urological treatments, familiar with combination therapies, drug delivery technologies, and adaptable medical solutions for diverse clinical environments
Obviousness Rationale
A PHOSITA would recognize that the core therapeutic approach of combining mast cell inhibitors and histamine receptor antagonists remains consistent across the source patent and PTD. The PTD's environmental adaptations represent predictable engineering modifications to extend the treatment's applicability, utilizing standard design techniques for medical devices and drug delivery systems that address specific operational constraints.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,531 |
|---|---|
| Title | Combination mast cell inhibition for treatment of BPH/LUTS |
| Assignee(s) | Northwestern University |